Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 671 - 680 of 764 studies

Oral and Gastrointestinal

A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (MACARONI-23)

Neurological

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (XPF-010-303)

Cancer and neoplasms

An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly Diagnosed Multiple Myeloma (MagnetisMM6)

Metabolic and Endocrine

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia

A study of neuro-immune mechanisms in brain health from bio-samples (ANIMATE)

Cancer and neoplasms

A Phase Iii, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Inavolisib In Combination With Phesgo Versus Placebo In Combination With Phesgo After First Line Induction Therapy In Participants With Pik3ca‑Mutated Her2-Positive Locally Advanced Or Metastatic Breast Cancer (INAVO122)

NIHR BioResource for Translational Research - linked to NIHR203975 PID 16514

Cancer and neoplasms

Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors (AZD5863)

Cancer and neoplasms

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GEMINI Gastric)

NIHR HIC Patient Blood Management and Perioperative Care